Fig. 1.

Patient survival and tumor characteristics are identical whether tumors have stable, dominant-negative p53 mutations or non-dominant-negative mutations. Overall survival curves and clinical characteristics of patients with TP53 mutant ovarian, breast and lung cancers were stratified by mutation type and/or occurrence of loss of heterozygosity (LOH) at TP53 locus. a–c Overall survival and clinical data for ovarian, breast, and lung cancer patients in the TCGA (lung/ovarian) and METABRIC (breast) datasets with DN, non-DN, and DN-stable TP53 mutant tumors accessed through cBioportal. “DN-stable” refers to DN TP53 mutations that others have shown to result in a stabilized protein: R175H, G245D/S, R248Q/W/L, R249S, R273C/H/L, and R282W. d–f Clinical data for ovarian, breast, and lung cancer patients in the TCGA and METABRIC datasets with DN and non-DN TP53 mutant tumors stratified by occurrence of LOH at TP53 locus